Abozaid Omayma A R, El-Sonbaty Sawsan M, Hamam Neama M A, Farrag Moustafa A, Kodous Ahmad S
Clinical Biochemistry Department, Faculty of Veterinary Medicine, Benha University, Moshtohor, Egypt.
Radiation Microbiology Department, National Center for Radiation Research and Technology, Egyptian Atomic Energy Authority, Cairo, Egypt.
Biol Trace Elem Res. 2023 Jan;201(1):306-323. doi: 10.1007/s12011-022-03140-7. Epub 2022 Mar 2.
This study investigates the antidiabetic and antioxidant potential of chitosan-encapsulated selenium nanoparticles in streptozotocin-induced diabetic model. Glibenclamide was used as a reference antidiabetic drug. Forty-eight adult male Wistar rats were used along the study and divided equally into 6 groups of (I) normal control, (II) chitosan-encapsulated selenium nanoparticles (CTS-SeNPs), (III) glibenclamide, (IV) streptozotocin (STZ), (V) STZ + CTS-SeNPs, and (VI) STZ + Glib. The animals were sacrificed on the 35th day of the experiment. Serum glucose, insulin, IGF-1, ALT, AST, CK-MB, oxidative stress, lipid profile, and inflammatory parameters were subsequently assessed. Also, the expression level of TCF7L2, CAPN10, and PPAR-γ genes were evaluated using qPCR. In addition, histopathological studies on pancreatic tissue were carried out. The results revealed that STZ induced both diabetes and oxidative stress in normal rats, manifested by the significant changes in the studied parameters and in the physical structure of pancreatic tissue. Oral administration of CTS-SeNPs or Glib results in a significant amelioration of the levels of serum fasting blood glucose, insulin, IGF-1, AST, ATL, and CK-MB as compared with STZ-induced diabetic rats. CTS-SeNPs and Glib diminished the level of lipid peroxidation, increased total antioxidant capacity level, as well as possessed strong inhibition against serum α-amylase and α-glucosidase activities. Diabetic animals received CTS-SeNPs, or Glib demonstrated a significant (p < 0.05) decrease in the expression level of TCF7L2 and CAPN10 genes with a significant increase in the expression level of PPAR-γ gene, compared to STZ group. The above findings clarify the promising antidiabetic and antioxidant effect of CTS-SeNPs, recommending its inclusion in the currently used protocols for the treatment of diabetes and in the prevention of its related complications.
本研究调查了壳聚糖包裹的硒纳米颗粒在链脲佐菌素诱导的糖尿病模型中的抗糖尿病和抗氧化潜力。格列本脲用作参考抗糖尿病药物。在整个研究过程中使用了48只成年雄性Wistar大鼠，并将其平均分为6组：（I）正常对照组，（II）壳聚糖包裹的硒纳米颗粒（CTS-SeNPs）组，（III）格列本脲组，（IV）链脲佐菌素（STZ）组，（V）STZ + CTS-SeNPs组，以及（VI）STZ + 格列本脲组。在实验的第35天处死动物。随后评估血清葡萄糖、胰岛素、IGF-1、ALT、AST、CK-MB、氧化应激、血脂谱和炎症参数。此外，使用qPCR评估TCF7L2、CAPN10和PPAR-γ基因的表达水平。另外，对胰腺组织进行了组织病理学研究。结果显示，STZ在正常大鼠中诱导了糖尿病和氧化应激，表现为所研究参数以及胰腺组织结构的显著变化。与STZ诱导的糖尿病大鼠相比，口服CTS-SeNPs或格列本脲可显著改善血清空腹血糖、胰岛素、IGF-1、AST、ATL和CK-MB的水平。CTS-SeNPs和格列本脲降低了脂质过氧化水平，提高了总抗氧化能力水平，并且对血清α-淀粉酶和α-葡萄糖苷酶活性具有强烈抑制作用。与STZ组相比，接受CTS-SeNPs或格列本脲的糖尿病动物的TCF7L2和CAPN10基因表达水平显著降低（p < 0.05），而PPAR-γ基因表达水平显著升高。上述发现阐明了CTS-SeNPs具有良好的抗糖尿病和抗氧化作用，建议将其纳入目前用于治疗糖尿病及其相关并发症的方案中。
